Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3483-3493

  Wong, Hon Kit ^a   Lahdenranta, Johanna ^a   Kamoun, Walid S ^a   Chan, Annie W ^b   McClatchey, Andrea I ^b   Plotkin, Scott R ^b   Jain, Rakesh K ^a   Di Tomaso, Emmanuelle ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VANDETANIB; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARACHNOID; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; CANCER IMMUNOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LASER MICROSCOPY; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; OVERALL SURVIVAL; PIA MATER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCIATIC NERVE; SURVIVAL RATE; TUMOR GROWTH; WESTERN BLOTTING; WHOLE BODY IMAGING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PIPERIDINES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951726598     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3107     Document Type: Article

References (41)

1. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000;14:1617-1630
2. Harner SG, Laws ER, Jr. Diagnosis of acoustic neurinoma. Neurosurgery 1981;9:373-379
3. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 2005;18:604-610
4. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-2134
5. Caye-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101.
6. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 2007;83:259-266
7. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, Brieger J. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 2007;28:1094-1099 (Pubitemid 350191085)
8. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-367
9. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 2005;16:535-548 (Pubitemid 41022016)
10. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002;515:33-48. (Pubitemid 36324180)
11. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004;114:1260-1271 (Pubitemid 40385297)
12. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147 (Pubitemid 38524883)
13. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139 (Pubitemid 46657433)
14. Batchelor TT, Sorensen GA, di Tomaso E, et al. AZD2171, a pan-VEGF and PDGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates vasogenic edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
15. Rich JN, Sathornsumetee S, Keir ST, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005;11:8145-8157 (Pubitemid 41698759)
16. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92 Suppl 1:S6-13.
17. Pan Q, Chanthery Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67. (Pubitemid 46054517)
18. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655
19. Hung G, Li X, Faudoa R, et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 2002;20:475-482
20. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47ΔHSV vector treatment of schwannomas. Cancer Gene Ther 2007;14:460-467
21. Winkler F, Kozin SV, Tong R, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 2004;6:553-563 (Pubitemid 40017699)
22. Lee JK, Sobel RA, Chiocca EA, Kim TS, Martuza RL. Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol 1992;14:101-112
23. Tyrrell JA, di Tomaso E, Fuja D, et al. Robust 3-D modeling of vasculature imagery using superellipsoids. IEEE Trans Med Imaging 2007;26:223-237
24. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-14770
25. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000;97:14608-14613
26. di Tomaso E, London N, Fuja D, et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 2009;4:e5123.
27. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 2008;5:487-491
28. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) 2006;42:657-670
29. Curto M, Cole BK, Lallemand D, Liu C-H, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007;177:893-903.
30. Maher PA, Schubert D. Schwannoma-derived growth factor interacts with the epidermal growth factor receptor. J Neurochem 1995;65:1895-1898
31. Scoles DR, Qin Y, Nguyen V, Gutmann DH, Pulst SM. HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun 2005;335:385-392
32. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-2552
33. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 2008;76:15-22.
34. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
35. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-3736
36. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-338
37. Rechthand E, Rapoport SI. Regulation of the microenvironment of peripheral nerve: role of the blood-nerve barrier. Prog Neurobiol 1987;28:303-343
38. Wadhwani KC, Rapoport SI. Transport properties of vertebrate blood-nerve barrier: comparison with blood-brain barrier. Prog Neurobiol 1994;43:235-279
39. Mizisin AP, Kalichman MW, Myers RR, Powell HC. Role of the blood-nerve barrier in experimental nerve edema. Toxicol Pathol 1990;18:170-185
40. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.
41. Poduslo JF, Curran GL. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci U S A 1992;89: 2218-2222